MDR Reform and the Future of Multilingual Compliance for Medical Device Companies

How documentation strategy, translation risk, and regulatory transparency are evolving in 2026 and beyond.

5 minutes

Since its implementation in 2017, the EU Medical Device Regulation (MDR) fundamentally reshaped how medical device companies manage documentation, oversight, and transparency across the device lifecycle.

Documentation volumes increased. Updates became continuous. Patient-facing content became mandatory. And centralized systems such as EUDAMED made regulatory information more visible and easier to review across Member States.

Now, with the European Commission’s 2025 MDR / IVDR reform proposal, manufacturers are asking an important question: What changes and what stays the same when it comes to multilingual regulatory documentation?

The answer is nuanced. Administrative burden may decrease. Safety expectations do not. And language remains embedded in market access.

How MDR Transformed Documentation and Language Requirements

Under MDR, regulatory philosophy shifted from lighter oversight to evidence-driven, lifecycle-based regulation.

For manufacturers, this meant:

Language moved from a transactional activity at the end of the process to a regulated control layer embedded in submissions, updates, and public-facing documentation.

Translation errors could delay CE marking. Inconsistent terminology could raise audit findings. Patient-facing content required clarity, accuracy, and alignment across EU languages.

In practical terms, language became part of regulatory infrastructure.

The 2025 MDR / IVDR Reform: What Is Changing?

In December 2025, the European Commission proposed targeted updates to reduce unnecessary administrative steps while maintaining medical device safety requirements. The intent of the reform is not deregulation, it is simplification.

Proposed changes include fewer repetitive documentation cycles, updates triggered primarily by material device changes, potential flexibility for certain professional-only documentation (pending final legislative text), and improved predictability in regulatory timelines. For manufacturers, this may mean fewer large portfolio refreshes and less annual documentation churn. However, the core regulatory standards remain intact.

What the Reform Does Not Change

Despite administrative adjustments, the following remain unchanged:

Language obligations do not disappear under reform. They become more targeted and, in many cases, more strategic. Updates may occur less frequently. But when they occur, they carry greater weight.

Why Translation Strategy Becomes More Important, Not Less

A common assumption is that fewer documentation cycles mean less translation demand. In reality, the shift changes how translation is purchased and managed. Under the post-reform environment, large bulk refreshes may decrease while change-driven updates increase, turnaround expectations tighten, audit-readiness remains essential, and documentation traceability becomes critical.

Manufacturers are increasingly asking:

Translation is no longer volume-driven. It becomes precision-driven.

Industry Concerns: What Manufacturers Are Saying

Recent industry feedback collected during the reform consultation highlighted recurring themes:

These concerns do not eliminate translation requirements. They elevate the need for defensible, scalable multilingual processes. Manufacturers are not looking to reduce compliance. They are looking to manage it more intelligently.

What Defensible Multilingual Compliance Looks Like in 2026–2027

In a post-reform environment, multilingual compliance requires more than accurate translation. It requires controlled systems.

Effective multilingual regulatory support now includes:

The goal is not simply to translate documents. It is to maintain alignment across languages over time under regulatory scrutiny.

The Strategic Shift: From Transactional Translation to Regulatory Infrastructure

Before MDR, translation was often viewed as an end-stage operational task. After MDR, it became embedded in regulatory submissions. After reform, it becomes strategic infrastructure.

Medical device companies planning for 2026–2027 documentation strategies should evaluate how multilingual updates are triggered and tracked, whether translation workflows are change-driven or document-driven, how terminology is governed across product lifecycles, whether documentation is defensible during inspection or audit, and how automation can be safely integrated without increasing risk. This is not simply about cost control. It is about risk control and predictability.

How Welo Life Sciences Supports Multilingual Compliance Under MDR Reform

Welo Life Sciences works with medical device companies to manage multilingual documentation as a lifecycle discipline rather than a series of disconnected projects.

Our approach focuses on:

As MDR reform reshapes administrative cycles, the need for structured, defensible multilingual documentation becomes more important.

Language remains market access infrastructure.

Planning Ahead for 2026–2027

The MDR reform may reduce unnecessary paperwork cycles. It does not reduce regulatory scrutiny.

For medical device companies, the path forward includes:

Organizations that treat multilingual documentation as a strategic compliance system, rather than a cost center, will be better positioned to navigate the next phase of EU regulation.

Preparing Your Multilingual Documentation Strategy

If your team is preparing documentation plans for 2026–2027 and evaluating how MDR reform affects translation scope, update cycles, and regulatory risk, Welo Life Sciences can help assess readiness and design a scalable multilingual documentation support model aligned with evolving EU expectations.

Welo Life Sciences works with device teams to evaluate readiness and design scalable documentation workflows aligned with evolving EU expectations.

Talk to a Medical Device Specialist →